Ardelyx is executing on a strong commercial ramp, with Q2 2026 revenue reaching a record $120.9M (+23.8% YoY) and gross margins expanding to 95.2%, driven by IBSRELA and XPHOZAH uptake. However, the company remains unprofitable at the operating line (-10.3% op...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.07-7.0% vs -$0.07 | $121M-0.1% vs $121M |
Q2 2026 Apr 30, 2026 | -$0.15-15.4% vs -$0.13 | $94M+1.8% vs $93M |
Q1 2026 Feb 19, 2026 | $0.02+0.0% vs $0.02 | $125M+6.1% vs $118M |
Q4 2025 Oct 30, 2025 | -$0.00+93.3% vs -$0.06 | $110M-7.3% vs $119M |
WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following investor conferences:
Freestone Grove Partners LP bought a new position in Ardelyx, Inc. (NASDAQ: ARDX) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 253,692 shares of the biopharmaceutical company's stock, valued at approximately $1,294,000. Freestone Grove Partners LP owned 0.10% of
Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript
ARDX, ARDT and GPRE have been added to the Zacks Rank #5 (Strong Sell) List on August 7th, 2026.
Benchmark ARDX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Ardelyx, Inc. (ARDX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.48 | $859.66M | -13.38 | 22.09% | -15.12% | -36.21% | — | |
| $23.52 | $15.73M | -3.08 | 3.7% | -353% | -87.96% | — | |
| $1.26 | $154.24M | -0.87 | -84.2% | -257.1% | -181.73% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — | |
| $20.24 | $1.49B | 6.13 | 18.52% | 80.56% | 30.03% | — | |
| $43.39 | $2.52B | -63.81 | 8.63% | -13.23% | -10.42% | — |
Ardelyx, Inc. (ARDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Ardelyx, Inc. (ARDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 2, 2026·SEC
Jun 17, 2026·SEC
Get notified when ARDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ardelyx, Inc. (ARDX) stock FAQ — growth, dividends, profitability & financials explained
Ardelyx, Inc. (ARDX) reported $450.9M in revenue for fiscal year 2025. This represents a 8234% increase from $5.4M in 2012.
Ardelyx, Inc. (ARDX) grew revenue by 22.1% over the past year. This is strong growth.
Ardelyx, Inc. (ARDX) reported a net loss of $55.7M for fiscal year 2025.
Ardelyx, Inc. (ARDX) has a return on equity (ROE) of -36.2%. Negative ROE indicates the company is unprofitable.
Ardelyx, Inc. (ARDX) had negative free cash flow of $17.9M in fiscal year 2025, likely due to heavy capital investments.
